Antagonists for kinin B-1 and B-2 receptors in the mouse

被引:16
作者
Allogho, SN [1 ]
Gobeil, F [1 ]
Pheng, LH [1 ]
NguyenLe, XK [1 ]
Neugebauer, W [1 ]
Regoli, D [1 ]
机构
[1] UNIV SHERBROOKE, SCH MED, DEPT PHARMACOL, SHERBROOKE, PQ J1H 5N4, CANADA
关键词
kinins; receptors; antagonists; tissues; mouse;
D O I
10.1139/cjpp-75-6-558
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Contractile responses to B-1 and B-2 receptor agonists have been demonstrated in the mouse stomach; the mouse urinary bladder responds only to B-2 receptor agonists. These tissues were used in this study to investigate the antagonistic effect of four B-2 receptor antagonists, namely, DArg[Hyp(3),DPhe(7),Leu(8)]BK (BK, bradykinin), HOE-140, WIN 64338, and FR-173657 (B-2 receptor antagonists), as well as three B-1 kinin receptor antagonists; [Leu(8)]desArg(9)BK, Lys[Leu(8)]desArg(9)BK, and AcLys[D beta Nal(7),Ile(8)]desArg(9)BK, were investigated. Results shown indicate that DArg[Hyp(3),DPhe(7),Leu(8)]BK is a partial agonist, while HOE-140 and FR-173657 are pure antagonists, devoid of direct myotropic effects, and quite selective for the B-2 receptor. WIN 64338 was essentially inactive on both B-1 and B-2 receptors. The myotropic effect of DArg[Hyp(3),DPhe(7),Leu(8)]BK is blocked by HOE-140. Similarly, Lys[Leu(8)]desArg(9)BK and [Leu(8)]desArg(9)BK are B-1 receptor partial agonists whose activities are blocked by AcLys[D beta Nal(7),Ile(8)]desArg(9)BK (code name R 715), a fairly pure B-1 receptor antagonist. Both HOE-140 and FR-173657 are long-acting, slowly reversible compounds that exert a noncompetitive type of antagonism, while R 715 is rapidly reversible and, thus, possibly competitive. Data presented in this paper provide a pharmacological characterization of B-1 and B-2 receptor antagonists in the mouse and underline the positive features of FR-173657 as a potent and selective B-2 receptor antagonist, as well as the potency and purity of R 715 as a B-1 receptor antagonist in the mouse.
引用
收藏
页码:558 / 562
页数:5
相关论文
共 11 条
[1]   Kinin B-1 and B-2 receptors in the mouse [J].
Allogho, SN ;
Gobeil, F ;
Pheng, LH ;
NguyenLe, XK ;
Neugebauer, W ;
Regoli, D .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1995, 73 (12) :1759-1764
[2]  
DRAPEAU G, 1988, METHOD ENZYMOL, V163, P263
[3]   Receptors for kinins in the human isolated umbilical vein [J].
Gobeil, F ;
Pheng, LH ;
Badini, I ;
NguyenLe, XK ;
Pizard, A ;
Rizzi, A ;
Blouin, D ;
Regoli, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (02) :289-294
[4]  
GOBEIL F, 1996, ANTAGONISTS HYPERTEN, V28, P833
[5]  
MENKE JG, 1994, J BIOL CHEM, V269, P21583
[6]  
REGOLI D, 1980, PHARMACOL REV, V32, P1
[7]   STRUCTURE-ACTIVITY STUDIES OF BRADYKININ AND RELATED PEPTIDES - B2-RECEPTOR ANTAGONISTS [J].
RHALEB, NE ;
TELEMAQUE, S ;
ROUISSI, N ;
DION, S ;
JUKIC, D ;
DRAPEAU, G ;
REGOLI, D .
HYPERTENSION, 1991, 17 (01) :107-115
[8]   STRUCTURE-ACTIVITY STUDIES ON BRADYKININ AND RELATED PEPTIDES - AGONISTS [J].
RHALEB, NE ;
DRAPEAU, G ;
DION, S ;
JUKIC, D ;
ROUISSI, N ;
REGOLI, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 99 (03) :445-448
[9]   PA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM [J].
SCHILD, HO .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1947, 2 (03) :189-206
[10]  
SCHILD HO, 1973, DRUG RECEPTORS, P1129